Belite Bio, Inc (BLTE) Research

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Market snapshot

Symbol
BLTE
Price
$146.12
Day change
-1.50%
Market cap
$5.9B
P/E ratio
-64.53x
52-week range
56.1-200
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$208

Peer companies

  • ACADIA Pharmaceuticals Inc. (ACAD)
  • ADMA Biologics, Inc. (ADMA)
  • Arcutis Biotherapeutics, Inc. (ARQT)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • Dyne Therapeutics, Inc. (DYN)
  • Ligand Pharmaceuticals Incorporated (LGND)
  • Mirum Pharmaceuticals, Inc. (MIRM)
  • Praxis Precision Medicines, Inc. (PRAX)

Recent insider activity

  • Scholl Hendrik Peter — S-Sale (2054 shares) on 2026-06-16
  • Scholl Hendrik Peter — S-Sale (784 shares) on 2026-06-16
  • Scholl Hendrik Peter — S-Sale (3140 shares) on 2026-06-16
  • Scholl Hendrik Peter — S-Sale (540 shares) on 2026-06-16
  • Scholl Hendrik Peter — S-Sale (100 shares) on 2026-06-16

Open Belite Bio, Inc (BLTE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.